CHU de Rennes
Rennes, 35000, France
NCT Number: NCT03481686
In chronic kidney disease, ESAs (Erythropoiesis-stimulating agents) are used to treat anemia. This anemia is due to decreased renal production of erythropoietin (EPO), a hormone that stimulates the production of red blood cells in the bone marrow. Treatment of anemia increases survival, decreases morbidity and improves quality of life and exercise tolerance.
Self-administration of ASE has been encouraged for many years, notably with pens for injection, but only few patients are educated in the injection technique.
The investigators therefore wish to lead a study in the Nephrology department of Rennes University Hospital to educate the patient, or his or her spouse, on ESA injections during hospitalization, in order to empower the patient in his care, and with the second aim of reducing the costs of chronic renal insufficiency.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Rennes, 35000, France
Erythropoiesis-stimulating agents (ESAs) are numerous and prescribed, depending on the molecule, once a week to once a month. They have improved the management of pre-dialysis patients, increased their hemoglobin and decreased transfusion needs, improving their morbidity and mortality and quality of life.
They are administered in pre-dialysis or post-renal transplantation most often by subcutaneous injection, which can be done by the patient himself, a member of his family or a nurse. Self-administration of ASE has been encouraged for many years, notably with pens for injection, but only few pilot studies show the feasibility of these auto-injections of ASE and patient satisfaction.
In 2012, the investigators conducted a practice study whose main objective was to have a picture of ESA injection practices for pre-dialysis patients. It is an observational, epidemiological, prospective and multicentric study, carried out by a questionnaire completed by the nephrologist during a consultation.
At the end of a 6-month collection period, 143 records were collected. All the patients questioned were followed for chronic renal insufficiency, not yet dialysed and not transplanted.
The majority of patients enrolled in this study were in the maintenance phase for ASE prescription (86% versus 14% in the correction phase), the mean age was 66.4 +/- 16.9 years. In 70.2% of cases the injection is done by a nurse, compared to 24.8% of injections made by the patient himself and 4.9% by his spouse. For 86.7%, the injection was done at home, and for 60% without other associated care. The nurse therefore came only for the injection of ASE. Not surprisingly, at an equal ASE cost, the resort to a nurse is significantly more expensive.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will perform ASE injections themselves or by their spouses
Time frame: 6 months
Time frame: 1 month
Time frame: 3 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Treatment compliance
Time frame: 6 months
pain assessment with a visual analog scale (0 = no pain, 10 = maximum pain)
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
evaluation of reason for stopping self-injections with a questionnaire
Time frame: 6 months
Time frame: 6 months
evaluation of reason for refusing therapeutic education with a questionnaire
Rennes University Hospital
Other
SelfEPO - Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections
Acronym: SELFEPO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04190251
Behavior, Chronic Disease
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsNCT05565716
Cardiovascular Diseases, Chronic Disease
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT03381950
Chronic Disease, Disease Attributes
Villejuif, France
View Trial DetailsNCT04876963
Arrhythmias, Cardiac, Cardiovascular Diseases
Copenhagen, Denmark
View Trial Details